Scientist / Senior Scientist
Precede Biosciences
Scientist / Senior Scientist
Precede Biosciences
Epigenomic liquid biopsy for cancer.
Salary Range: 125000 to 175000 (Currency: USD) (Pay period: per-year-salary)
About Precede Biosciences
We are pioneering an advanced, minimally invasive, comprehensive epigenomics platform with the potential to profoundly impact the research and development of new medicines and the use of approved medicines in clinical practice across a number of conditions, including cancer. More information on our company and platform can be found on our company website and in our seminal publication in Nature Medicine.
We care deeply about creating a place where folks can do their best work from the start and have intentionally created an environment that is defined by purpose, teamwork, and excellence. This means nurturing team spirit, facing challenges together, collaboratively solving complex problems, while also ensuring a strong focus on individual initiative, accountability, and delivery.
Epigenomic liquid biopsy for cancer.
Precede Biosciences uses a blood test to read epigenomic signals in plasma. It analyzes circulating chromatin and the DNA methylome from a single milliliter of blood to determine the activation status of about 20,000 gene promoters and 1 million gene enhancers, providing a transcriptional biology view of disease. The platform supports drug development through Research Use Only partnerships with biopharmaceutical companies and academia, and aims to develop clinical blood-based tests that can replace invasive tissue biopsies for guiding precision medicines in cancers such as breast, lung, prostate, and colorectal. Unlike purely genomic tests, this approach focuses on epigenomic regulation to reveal disease biology, treatment response, and resistance. The company seeks to help identify therapeutic targets and mechanisms driving outcomes, with a goal of accelerating biomarker discovery and enabling non-invasive, dynamic insights into cancer biology.
Explore more opportunities at Precede Biosciences